Sunshine Biopharma Files Draft Information Statement
Bitget2026/10/14 21:22- Sunshine Biopharma's draft information statement outlines shareholder authorization for discounted share issuance exceeding 20% of outstanding common stock.
- The October 13, 2026, authorization covers Series D Warrant exercise-price adjustments and proportional underlying share adjustments following share combinations.
- Share-combination adjustments could lower the initial $0.66 exercise price to a minimum of $0.275, increasing shares issuable proportionately.
- Shareholders also authorized voluntary reductions in Series D Warrant exercise prices at the board's discretion.
- The warrants were issued in an offering that closed October 9, 2026, raising approximately $6 million in gross proceeds.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
New York Federal Reserve Survey: Service Sector Price Increases Hit Fastest Pace Since 2022, Business Activity Index Drops to Lowest Since March
A survey released by the New York Fed on Friday shows that in October, sales prices for service sector firms increased at the fastest pace since 2022, with input costs remaining robust and supply conditions continuing to deteriorate. Businesses’ pessimism about the commercial outlook has significantly intensified, with the overall business activity index falling by 12 points from the previous month to minus 20.7, marking the weakest reading since March.
Raoul Pal Holds Bitcoin, Solana and Ethereum, but Calls One Wildly Undervalued
Ethos Technologies President Wang Lingke Reports Sale of $4.54 Million in Common Shares
Exclusive report - Boeing memorandum says sales chief McMullen will retire
Crypto prices
More
